Interim report 1 January – 31 March 2024

Positive profitability trend driven by Medtech


  
During the quarter, profitability strengthened in line with our priorities and organic sales increased by 4%. Labtech's sales performance was temporarily weaker, but the companies were largely able to defend their margins. Medtech delivered strong growth and it is gratifying to see a gradual improvement in profitability, driven in part by implemented improvement actions. 
   

Fredrik Dalborg, President and CEO 

1 JANUARY – 31 MARCH 2024 (3 MONTHS)

  • Net sales increased by 5% to SEK 2,570 m (2,457). The organic growth, excluding exchange rate changes, was 4%. 
  • EBITA decreased by 20% to SEK 291 m (366), corresponding to an EBITA-margin of 11.3% (14.9). EBITA previous year included reversed contingent considerations of SEK 83 m. Adjusted for this EBITA increased by 3% and the EBITA margin previous year amounted to 11.5%.
  • Profit for the period amounted to SEK 63 m (174).
  • Earnings per share amounted to SEK 0.52 (1.43). Earnings per share for the last 12 months amounted to SEK 0.65 (3.54)
  • Cash flow from operating activities amounted to SEK 97 m (105).
  • The equity ratio was 39% (39).
  • Return on working capital (P/WC) amounted to 46% (50).
  3 months ending 12 months ending
SEKm 31 Mar 24 31 Mar 23 change 31 Mar 24 31 Dec 23
Net sales 2,570 2,457 5% 9,798 9,685
EBITA 291 366 -20% 1,060 1,135
EBITA-margin 11.3% 14.9%   10.8% 11.7%
Profit before tax 100 206 -51% 233 339
Profit for the period 63 174 -64% 81 192
Earnings per share before dilution, SEK 0.52 1.43 -64% 0.65 1.56
Earnings per share after dilution, SEK 0.52 1.42 -63% 0.65 1.56
Dynamisk graf: Net sales (SEKm)
Dynamisk graf: EBITA (SEKm)
  3 months ending
One-off costs, SEKm 31 Mar 24 31 Mar 23
Restructuring reserve Camanio Health -6 –
Reversed contingent consideration – 83
Total one-off costs -6 83
     
  3 months ending
Classification in income statement, SEKm 31 Mar 24 31 Mar 23
Cost of sales – –
Selling expenses -1 –
Administrative expenses -2 –
Research and Development -3 –
Other operating income and expenses – 83
Total one-off costs in the income statement -6 83
Latest updated: 4/23/2024 3:10:41 PM by Eva Berger
NEXT